Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Adressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

SGLT2 inhibitor improves HF outcomes and CV death in HF patients irrespective of T2DM status

Literature - Sep. 19, 2019

EASD 2019 Both HF patients with and without T2DM showed about 25% reduction of worsening HF and CV death when treated with dapagliflozin in the DAPA-HF study, and symptoms improved.

Early benefit on health status with ARNI treatment in HFrEF patients

Literature - Sep. 17, 2019 - Khariton Y et al.., - JACC: Heart Failure. 2019

Real-world data of the CHAMP-HF registry show that patients initiating sacubitril/valsartan experience improvements in KCCQ physical limitation and QoL domains during a median of 57 days.

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller
A strategy of early and sustained vasodilation in acute HF patients was unable to reduce all-cause death and rehospitalization for acute HF.

ESC 2019 A strategy of early and sustained vasodilation in acute HF patients was unable to reduce all-cause death and rehospitalization for acute HF.

Beta-blockers can reduce mortality in HFrEF in sinus rhythm, even in those with renal dysfunction

News - Sep. 2, 2019
The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

ESC 2019 The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

Comprehensive vasodilation strategy fails to improve outcomes in acute HF

News - Sep. 2, 2019
Early intensive and sustained vasodilation with individualized doses of well-characterized drugs in adults with AHF did not improve all-cause mortality and AHF hospitalizations.

ESC 2019 Early intensive and sustained vasodilation with individualized doses of well-characterized drugs in adults with AHF did not improve all-cause mortality and AHF hospitalizations.

SGLT2 inhibitor reduces CV death and worsening HF events in HFrEF patients

News - Sep. 1, 2019
In HFrEF patients with and without diabetes, dapagliflozin therapy reduced the composite of CV death and worsening HF events compared to placebo.

ESC 2019 In HFrEF patients with and without diabetes, dapagliflozin therapy reduced the composite of CV death and worsening HF events compared to placebo.

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray
DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon
Sacubitril/valsartan was tested in HFpEF patients in the PARAGON-HF trial. The reduction in HF hospitalizations and CV death just missed significance, but heterogeneity was seen for the treatment effect.

ESC 2019 Sacubitril/valsartan was tested in HFpEF patients in the PARAGON-HF trial. The reduction in HF hospitalizations and CV death just missed significance, but heterogeneity was seen for the treatment effect.

Primary endpoint just missed significance in trial evaluating ARNI in HFpEF patients

News - Sep. 1, 2019
Sacubitril/valsartan, compared with valsartan, showed a non-significant reduction of 13% in HF hospitalization and CV death. Secondary outcomes suggest a benefit in some patients.

ESC 2019 Sacubitril/valsartan, compared with valsartan, showed a non-significant reduction of 13% in HF hospitalization and CV death. Secondary outcomes suggest a benefit in some patients.

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp
Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

ESC HF 2019 Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

High risk of sudden cardiac death in HIV-positive persons with HF

Literature - Aug. 26, 2019 - Alvi RM et al., - JACC Heart Fail. 2019

Persons with HIV-infection and HF showed a higher rate of SCD than uninfected subjects with HF. Better HIV disease control measures were associated with lower, but not background SCD rates.

Optimal doses of HF medication substantially lower in women with HF

News - Aug. 26, 2019

Optimal doses of HF medication in women with HF is around 50% of currently recommended dose and women with HF benefit from lower doses of HF medication.